Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 86, Issue 2, 2013, Pages 161-175

  Monk, Bradley J ^a   Dalton, Heather ^a   Farley, John H ^a   Chase, Dana M ^a   Benjamin, Ivor ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis inhibitors; Bevacizumab; Epithelial ovarian cancer; Molecular targeted therapy; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; NINTEDANIB; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; TOPOTECAN; TREBANANIB;

ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAINTENANCE CHEMOTHERAPY; METABOLIC DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876077447     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.09.012     Document Type: Review

References (85)

1. Pliarchopoulou K., Pectasides D. Epithelial ovarian cancer: focus on targeted therapy. Critical Reviews in Oncology/Hematology 2011, 79:17-23.
2. Bolis G., Danese S., Tateo S., et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. International Journal of Gynecological Cancer 2006, 16(Suppl 1):74-78.
3. Markman M., Liu P.Y., Wilczynski S., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. Journal of Clinical Oncology 2003, 21:2460-2465.
4. Pfisterer J., Weber B., Reuss A., et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute 2006, 98:1036-1045.
5. De Placido S., Scambia G., Di Vagno G., et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. Journal of Clinical Oncology 2004, 22:2635-2642.
6. Bookman M.A. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Annals of Oncology 2010, 21(Suppl 7):vii211-vii217.
7. Piccart M.J., Floquet A., Scarfone G., et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. International Journal of Gynecological Cancer 2003, 13(Suppl 2):196-203.
8. Pecorelli S., Favalli G., Gadducci A., et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. Journal of Clinical Oncology 2009, 27:4642-4648.
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Ovarian Cancer. Including Fallopian Tube Cancer and Primary Peritoneal Cancer. V.2.2012. [accessed 08.02.12]. http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf.
10. Brown M.R., Blanchette J.O., Kohn E.C. Angiogenesis in ovarian cancer. Baillière's Best Practice and Research. Clinical Obstetrics and Gynaecology 2000, 14:901-918.
11. Ramakrishnan S., Subramanian I.V., Yokoyama Y., Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005, 8:169-182.
12. Burger R.A. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology 2011, 121:230-238.
13. Chen H., Ye D., Xie X., Chen B., Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecologic Oncology 2004, 94:630-635.
14. Santin A.D., Hermonat P.L., Ravaggi A., Cannon M.J., Pecorelli S., Parham G.P. Secretion of vascular endothelial growth factor in ovarian cancer. European Journal of Gynaecological Oncology 1999, 20:177-181.
15. Apte S.M., Bucana C.D., Killion J.J., Gershenson D.M., Fidler I.J. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecologic Oncology 2004, 93:78-86.
16. Dabrow M.B., Francesco M.R., McBrearty F.X., Caradonna S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecologic Oncology 1998, 71:29-37.
17. Henriksen R., Funa K., Wilander E., Backstrom T., Ridderheim M., Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Research 1993, 53:4550-4554.
18. Lu C., Thaker P.H., Lin Y.G., et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. American Journal of Obstetrics and Gynecology 2008, 198:477-479.
19. Matei D., Emerson R.E., Lai Y.C., et al. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 2006, 25:2060-2069.
20. Matei D., Kelich S., Cao L., et al. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biology and Therapy 2007, 6:1951-1959.
21. Wilczynski S.P., Chen Y.Y., Chen W., Howell S.B., Shively J.E., Alberts D.S. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Human Pathology 2005, 36:242-249.
22. Crickard K., Gross J.L., Crickard U., et al. Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecologic Oncology 1994, 55:277-284.
23. Di Blasio A.M., Cremonesi L., Vigano P., et al. Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. American Journal of Obstetrics and Gynecology 1993, 169:1517-1523.
24. Fujimoto J., Ichigo S., Hori M., Hirose R., Sakaguchi H., Tamaya T. Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers. European Journal of Gynaecological Oncology 1997, 18:349-352.
25. Steele I.A., Edmondson R.J., Bulmer J.N., Bolger B.S., Leung H.Y., Davies B.R. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001, 20:5878-5887.
26. Valve E., Martikainen P., Seppanen J., Oksjoki S., et al. Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors. International Journal of Cancer 2000, 88:718-725.
27. Whitworth M.K., Backen A.C., Clamp A.R., et al. Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clinical Cancer Research 2005, 11:4282-4288.
28. Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125:1591-1598.
29. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB Journal 2004, 18:338-340.
30. Batchelor T.T., Sorensen A.G., di T.E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
31. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer 2008, 8:592-603.
32. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
33. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation 2003, 111:1287-1295.
34. Laschke M.W., Elitzsch A., Vollmar B., Vajkoczy P., Menger M.D. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Human Reproduction 2006, 21:262-268.
35. Lu C., Kamat A.A., Lin Y.G., et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clinical Cancer Research 2007, 13:4209-4217.
36. AVASTIN® (bevacizumab) Solution for intravenous infusion [package insert]. South San Francisco, CA: Genentech, Inc.; 2011.
37. Burger R.A. Experience with bevacizumab in the management of epithelial ovarian cancer. Journal of Clinical Oncology 2007, 25:2902-2908.
38. Santos E.S., Gomez J.E., Raez L.E. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Investigational New Drugs 2012, 30:1261-1269.
39. NEXAVAR (sorafenib) tablets, oral [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc.; 2010.
40. Sorafenib Hasskarl J. Recent Results in Cancer Research 2010, 184:61-70.
41. GlaxoSmithKline Votrient® (pazopanib) prescribing information. [accessed 23.06.10]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf.
42. Sloan B., Scheinfeld N.S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Current Opinion in Investigational Drugs 2008, 9:1324-1335.
43. Lindsay C.R., MacPherson I.R., Cassidy J. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology 2009, 5:421-432.
44. Karlan B.Y., Oza A.M., Richardson G.E., et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. Journal of Clinical Oncology 2012, 30:362-371.
45. Mabuchi S., Terai Y., Morishige K., et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clinical Cancer Research 2008, 14:7781-7789.
46. Burger R.A., Sill M.W., Monk B.J., Greer B.E., Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2007, 25:5165-5171.
47. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. Journal of Clinical Oncology 2007, 25:5180-5186.
48. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Journal of Clinical Oncology 2008, 26:76-82.
49. Kudoh K., Takano M., Kouta H., et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecologic Oncology 2011, 122:233-237.
50. McGonigle K.F., Muntz H.G., Vuky J., et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 2011, 117:3731-3740.
51. Tillmanns T.D., Lowe M.P., Schwartzberg L.S., Walker M.S., Stepanski E.J. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Journal of Clinical Oncology 2010, 28. [Abstract 5009].
52. Wenham R., LaPolla J., Lin H., et al. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecologic Oncology 2010, 116:S61-S62. [Abstract 155].
53. Micha J.P., Goldstein B.H., Rettenmaier M.A., et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. International Journal of Gynecological Cancer 2007, 17:771-776.
54. Penson R.T., Dizon D.S., Cannistra S.A., et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. Journal of Clinical Oncology 2010, 28:154-159.
55. Burger R.A., Brady M.F., Bookman M.A., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine 2011, 365:2473-2483.
56. Perren T.J., Swart A.M., Pfisterer J., et al. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine 2011, 365:2484-2496.
57. Aghajanian C., Finkler N.J., Rutherford T., et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Journal of Clinical Oncology 2011, 29. [Abstract LBA5007].
58. Randall L.M., Monk B.J. Bevacizumab toxicities and their management in ovarian cancer. Gynecologic Oncology 2010, 117:497-504.
59. Han E.S., Monk B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecologic Oncology 2007, 105:3-6.
60. Hapani S., Chu D., Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncology 2009, 10:559-568.
61. Gonzalez-Martin A., Gladieff L., Tholander B., et al. Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA. Journal of Clinical Oncology 2012, 30. [Abstract 5017].
62. Pujade-Lauraine E., Hilpert F., Weber B., et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). Oral presentation at: the 48th annual meeting of the American society of clinical oncology 2012.
63. Hilberg F., Roth G.J., Krssak M., et al. BIBF, 1120, triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Research 2008, 68:4774-4782.
64. Ledermann J.A., Hackshaw A., Kaye S., et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. Journal of Clinical Oncology 2011, 29:3798-3804.
65. du Bois A., Huober J., Stopfer P., et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Annals of Oncology 2010, 21:370-375.
66. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004, 64:7099-7109.
67. Polcher M., Eckhardt M., Coch C., et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemotherapy and Pharmacology 2010, 66:203-207.
68. Matei D., Sill M.W., Lankes H.A., et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. Journal of Clinical Oncology 2011, 29:69-75.
69. Matei D., Ramasubbaiah R., Schilder J., et al. A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: HOG GYN-111. Journal of Clinical Oncology 2010, 28. [Abstract 5108].
70. Welch S.A., Hirte H.W., Elit L., et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. International Journal of Gynecological Cancer 2010, 20:787-793.
71. Kohn E.C., Lee J., Annunziata C.M., et al. A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naïve epithelial ovarian cancer (EOC) patients. Journal of Clinical Oncology 2011, 29. [Abstract 5019].
72. Kumar R., Knick V.B., Rudolph S.K., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular Cancer Therapy 2007, 6:2012-2021.
73. Friedlander M., Hancock K.C., Rischin D., et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic Oncology 2010, 119:32-37.
74. Matulonis U.A., Berlin S., Ivy P., et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. Journal of Clinical Oncology 2009, 27:5601-5606.
75. Hirte H.W., Vidal L., Fleming G.F., et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. Journal of Clinical Oncology 2008, 26. [Abstract 5521].
76. Raja F.A., Griffin C.L., Qian W., et al. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. British Journal of Cancer 2011, 105:884-889.
77. Coxon A., Bready J., Min H., et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Molecular Cancer Therapy 2010, 9:2641-2651.
78. Herbst R.S., Hong D., Chap L., et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. Journal of Clinical Oncology 2009, 27:3557-3565.
79. Stuart G.C., Kitchener H., Bacon M., et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. International Journal of Gynecological Cancer 2011, 21:750-755.
80. Roche. Media Release. Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer. [accessed 07.02.12]. http://www.roche.com/media/media_releases/med-cor-2011-12-23.htm.
81. Allegra C.J., Yothers G., O'Connell M.J., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. Journal of Clinical Oncology 2011, 29:11-16.
82. Cohn D.E., Kim K.H., Resnick K.E., O'Malley D.M., Straughn J.M. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. Journal of Clinical Oncology 2011, 29:1247-1251.
83. Jubb A.M., Harris A.L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncology 2010, 11:1172-1183.
84. Bamias A., Pignata S., Pujade-Lauraine E. Angiogenesis: A promising therapeutic target for ovarian cancer. Critical Reviews in Oncology/Hematology 2012, [Epub ahead of print].
85. Randall L.M., Sill M.W., Burger R.A., Monk B.J., Buening B., Sorosky J.I. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecologic Oncology 2012, 124:563-568.